[{"@context":"https:\/\/schema.org\/","@type":"BlogPosting","@id":"https:\/\/www.regionalcancercare.org\/news\/managing-lymphedema-in-breast-cancer-survivors\/#BlogPosting","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/managing-lymphedema-in-breast-cancer-survivors\/","headline":"Lymphedema in Breast Cancer Survivors: RCCA Oncologists Highlight 6 Key Points for Primary Care Clinicians","name":"Lymphedema in Breast Cancer Survivors: RCCA Oncologists Highlight 6 Key Points for Primary Care Clinicians","description":"Lymphedema in Breast Cancer Survivors: RCCA Oncologists Highlight 6 Key Points for Primary Care Clinicians August 5, 2026 There are more than 4 million breast cancer survivors in the United States today. And with approximately 320,000 new cases diagnosed each year and 5-year relative survival rates exceeding 99% for patients with localized disease, the ranks […]","datePublished":"2026-08-05","dateModified":"2026-08-05","author":{"@type":"Person","@id":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/#Person","name":"ceastway","url":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/","identifier":5,"image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Regional Cancer Care Associates","logo":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","width":506,"height":228}},"image":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2026\/08\/GettyImages-2273854039.jpg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2026\/08\/GettyImages-2273854039.jpg","height":483,"width":724},"url":"https:\/\/www.regionalcancercare.org\/news\/managing-lymphedema-in-breast-cancer-survivors\/","about":["All Cancers","Breast Cancer"],"wordCount":2142,"articleBody":"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tLymphedema in Breast Cancer Survivors: RCCA Oncologists Highlight 6 Key Points for Primary Care Clinicians\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tAugust 5, 2026\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tThere are more than 4 million breast cancer survivors in the United States today. And with approximately 320,000 new cases diagnosed each year and 5-year relative survival rates exceeding 99% for patients with localized disease, the ranks of survivors will grow rapidly over the next decade. Medical oncologists serve as those patients\u2019 lead physicians in terms of monitoring for cancer recurrence and managing the long-term sequelae of the disease and its treatment. However, primary care providers (PCPs) typically are the clinicians who survivors see most often once they complete initial treatment. In recognition of the vital role PCPs play in managing survivors\u2019 health, Regional Cancer Care Associates (RCCA) \u2013 one of the nation\u2019s largest networks of oncology specialists serving patients in New Jersey, Connecticut, Massachusetts, and the Washington, D.C., area.\u2013 is launching a series of occasional articles on conditions and quandaries primary care clinicians may encounter in providing care to breast cancer survivors. In the series\u2019 inaugural article, two board-certified medical oncologists and hematologists practicing with RCCA highlight six key points related to breast cancer-related lymphedema (BCRL).Treatment-Related Factors and Patient Characteristics Affect BCRL RiskBoth treatment-related factors and patient characteristics contribute to risk for BCRL. Deena Mary Atieh Graham, MD, explains, \u201cThe incidence of post-treatment lymphedema reported in the scientific literature ranges from the single digits to 50%, with many studies putting the rate around 20%. However, those are overall numbers looking at full study populations. The chances of developing lymphedema are significantly affected by both the type of surgical procedure and\/or radiation regimen involved and several patient characteristics.\u201d \u201cFor example, patients undergoing axillary lymph node dissection experience a BCRL incidence of roughly 19.9%, compared to 5.6% for patients who receive sentinel lymph node biopsy alone. Meanwhile, when regional nodal irradiation, or RNI, is administered following mastectomy, it increases the risk of lymphedema by up to five times. And when RNI is coupled with axillary lymph node dissection, the risk can escalate to upwards of 30% to 40%,\u201d says Dr. Graham, who practices with RCCA at the John Theurer Cancer Center of Hackensack University Medical Center in Hackensack, NJ.Rachel Levenbach, MD, who practices at RCCA\u2019s Moorestown, NJ office, notes that patient factors contributing to an elevated risk for BCRL include:Age >60 years at diagnosis;Body mass index >30, which can triple the risk of post-mastectomy lymphedema; and,Advanced tumor stage at diagnosis.Dr. Levenbach adds, \u201cIn order to counsel patients effectively and to have an appropriate index of suspicion for lymphedema, primary care clinicians need complete information on staging at diagnosis and the interventions that patients received. Electronic medical record platforms (EMRs) certainly have helped in this respect, but too often, the burden remains on the patient to remember and convey the specifics of her treatment regimen to her PCP. That is not realistic or reasonable and is unfair to both the patient and her clinician. At RCCA, we pride ourselves on providing our primary care colleagues with detailed information on a patient\u2019s diagnosis and treatment and of being available to them for quick consults or ongoing collaborative management.\u201dWhen Does Chronic BCRL Manifest?Chronic BCRL often manifests about 14 months after completion of treatment. Dr. Levenbach says,\u201cThe clinical timeline of BCRL is highly variable. While transient, mild swelling can occur within the first three months postoperatively due to acute surgical trauma or chemotherapy, true chronic BCRL typically manifests at an average of 14.4 months following treatment completion.\u201d She notes that while this is a time to be particularly attentive to possible lymphedema, breast cancer survivors remain at risk throughout their lives, with the baseline probability of onset increasing by roughly 1% per year for decades.\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\u201cThe chances of developing lymphedema are significantly affected by both the type of surgical procedure and\/or radiation regimen involved and several patient characteristics.\u201d\u2028\u2028\t\t\t\t\t\t\t\u2013 Deena Mary Atieh Graham, MD\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\u201cWe need to educate our patients with lymphedema that systemic symptoms such as fever, shivering, other flu-like symptoms, or sudden malaise can be the first indicators of cellulitis, emerging before the classic localized signs such as erythema, warmth, and pain.\u201d \u2028\u2028\t\t\t\t\t\t\t\t\u2013 Rachel Levenbach, MD\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tExercise and LymphedemaMany breast cancer survivors have misconceptions about exercise and lymphedema. \u201cMany years ago, oncologists advised breast cancer survivors to avoid resistance and aerobic exercises due to concerns that the physical activity could provoke or exacerbate lymphedema. Several studies have since allayed those concerns within the medical community, but the idea still has considerable traction among patients,\u201d Dr. Levenbach says. In fact, the cancer specialist adds, structured strength training optimizes the mechanical “muscle pump” action around deep lymphatic vessels, which actually improves extracellular fluid clearance and can prevent functional shoulder limitations.\u201cAs with so much in medicine and in life, common sense and moderation are key when it comes to exercise for breast cancer survivors,\u201d says Dr. Levenbach. She explains, \u201cFor example, patients should be advised to start slow, \u2018listen\u2019 to their bodies, and increase their exercise intensity gradually. They also should wear a physician- or therapist-recommended compression garment during exercise to offset any exercise-induced capillary filtration.\u201d Dr. Levenbach adds that referral to an exercise physiologist or physical therapist who has experience in working with breast cancer survivors can be particularly helpful in encouraging patients to adopt an individualized physical activity plan.Diagnosing BCRL with a Tape MeasureA tape measure often will suffice for diagnosing BCRL. Dr. Graham says that while imaging plays a key role in the ongoing monitoring of breast cancer survivors, a lower-tech tool \u2013 the tape measure \u2013 can reliably confirm the presence of lymphedema in many cases.\u201cI recommend performing serial, bilateral circumferential measurements of the arms at a few fixed points, such as at the metacarpophalangeal joints, wrists, 10 cm distal to the olecranon, and 10 cm proximal to the olecranon. A difference of 2 cm or greater at any corresponding point, or a calculated volumetric discrepancy of >10% between the affected and unaffected limbs, indicates lymphedema,\u201d Dr. Graham says. The medical oncologists adds that when questions remain after bilateral measurement of the limbs, referral for more sophisticated assessments, such as bioimpedance analysis, is indicated.How Is Lymphedema Treated?Complete decongestive therapy (CDT) remains the preferred first-line intervention for lymphedema. Once BCRL is identified, prompt \u2013 and ongoing \u2013 management is needed. \u201cComplete decongestive therapy is a multimodal, conservative intervention designed to maximize lymphatic diversion and is the preferred initial approach to treatment,\u201d Dr. Graham says. The medical oncologist adds that CDT is best coordinated by a Certified Lymphedema Therapist (CLT) and entails two phases:Phase I \u2013 Intensive Decongestion: Typically lasting 2 to 8 weeks, this phase focuses on reducing limb volume. Dr. Graham explains that it combines daily manual lymphatic drainage (MLD)\u2014a light, rhythmic skin-stretching massage that redirects fluid to functional lymphotomes\u2014with short-stretch, multi-layer compression bandaging, skin hygiene, and targeted exercises.Phase II \u2013 Maintenance: Self-management predominates in this phase. While maintenance regimens are individualized based on each patient\u2019s specific needs, they often encompass wearing custom-fitted, flat-knit compression garments during the day, utilizing adjustable wraps at night, performing self-administered MLD, and maintaining good skin health, Dr. Graham notes.Be Alert for Signs of CellulitisCellulitis is an ever-present concern. Dr. Levenbach notes that the long-term management of BCRL focuses on the prevention and aggressive treatment of secondary dermatological infections. \u201cBecause lymphostasis impairs localized immune surveillance, the lymphedematous limb is highly vulnerable to bacterial entry,\u201d she says, stressing that cellulitis in a lymphedematous limb is a medical emergency that can rapidly induce systemic sepsis and permanently damage remaining lymphatic channels. \u201cWe need to educate our patients to be alert to the prodromal systemic signs of infection, explaining to them that fever, shivering, other flu-like symptoms, or sudden malaise can be the first indicators of cellulitis, emerging before the classic localized signs such as erythema, warmth, and pain,\u201d she says. Dr. Graham says, \u201cLymphedema is among the most physically debilitating and psychologically distressing complications of breast cancer. While advanced surgical techniques such as lymphovenous anastomosis and vascularized lymph node transfer are offering new hope to patients with advanced or refractory cases, conservative measures will suffice for most breast cancer survivors with BCLR. With close communication and collaboration, primary care clinicians and medical oncologists can protect the physical health and enhance the quality of life of our patients experiencing lymphedema.\u201dFind Expert Breast Cancer Care Near You in NJ, CT, MA, and the Washington, D.C., AreaDr. Graham and Dr. Levenbach are among 90+ medical oncologists and hematologists who practice with Regional Cancer Care Associates (RCCA), one of the nation\u2019s largest networks of oncology specialists. RCCA has more than 20 locations near you across New Jersey, Connecticut, Massachusetts, and the Washington, D.C., area. RCCA\u2019s cancer specialists see more than 30,000 new patients each year and provide care to more than 265,000 established patients, collaborating closely with those patients\u2019 other physicians. RCCA physicians offer patients innovative therapies, including immunotherapies and targeted therapy, as well as access to approximately 300\u00a0clinical trials. In addition to serving patients who have solid tumors, blood-based cancers, and benign blood disorders, RCCA care centers also provide\u00a0infusion services to people with a number of non-oncologic conditions\u2014including\u00a0multiple sclerosis,\u00a0Crohn\u2019s disease,\u00a0asthma, iron-deficiency anemia, and\u00a0rheumatoid arthritis\u2014who take intravenously-administered medications.To learn more about RCCA, call 844-346-7222 or contact RCCA.\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tReferencesAllam O, Park KE, Chandler L, et al. The impact of radiation on lymphedema: a review of the literature. Gland Surgery. 2020;9(3):596\u2013602.American Cancer Society. Key statistics for breast cancer. Available at https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/key-statistics.html. Accessed July 6, 2026.American Cancer Society. Survival rates for breast cancer. Available at https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-survival-rates.html. Accessed July 6, 2026.BreastCancer.org. Complete decongestive therapy for lymphedema. Available at https:\/\/www.breastcancer.org\/treatment-side-effects\/lymphedema\/treatments\/complete-decongestive-therapy. Accessed July 12, 2026.Gillespie TC, Sayegh HE, Brunelle CL, Daniell KM, Taghian AG. Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments. Gland Surg. 2018;7(4):379-403.He L, Qu H, Wu Q, Song Y. Lymphedema in survivors of breast cancer. Oncology Letters. 2020;19(3):2482-2486.Kim JS, Kim JH, Chang JH, et al. Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis. Front Oncol. 2022;12.1026043. https:\/\/doi.org\/10.3389\/fonc.2022.1026043.Knopf, E. Comprehensive overview of management and risk assessment of breast cancer-related lymphedema: a multidisciplinary approach. Front Oncol. 2026:16: 1796657.Lymphoedema Support Network. About Cellulitis. Available at https:\/\/www.lymphoedema.org\/cellulitis\/about-cellulitis\/. Accessed July 14, 2026.Marchica P, D\u2019Arpa S, Magno S, et al. Integrated treatment of breast cancer-related lymphedema: a descriptive review of the state of the art. Anticancer Research. 2021;41(7): 3233\u20133246.McDuff SGR Mina AI, Brunelle CL, et al. Timing of lymphedema following treatment for breast cancer: when are patients most at risk? Int J Radiat Oncol Biol Phys. 2018;103(1):62\u201370. LymphaticShamsesfanabadi P, Abadi MSE, Yin Y, et al. Resistance training and lymphedema in breast cancer survivors. JAMA Netw Open. 2025;8;(6):e2514765. doi:10.1001\/jamanetworkopen.2025.14765Sleigh BC. Lymphedema. StatPearls. Available at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537239\/. Accessed July 10, 2026.Sueangamiam K, Rongsriyam K. The prevalence of arm lymphedema after radiation treatment in patients with breast cancer. J Radiother Prac. 2021: 22, e1-e7. https:\/\/doi.org\/10.1017\/s1460396921000418Tsai RJ, Dennis LK, Lynch CF, et al. Lymphedema following breast cancer: The importance of surgical methods and obesity. Front Womens Health. 2018; 31;3(2):10.15761\/FWH.1000144.\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tMelanoma By the NumbersAll statistics are for the United States and, unless otherwise noted, for 2026.Estimated new diagnoses: 112,000Percentage of all new cancer diagnoses: 5.3%Median age at diagnosis: 67 yearsPercentage of patients with regional or distant disease at diagnosis: 15%Estimated number of deaths: 8,510Percentage of all cancer deaths: 1.4%5-year overall relative survival rate 2016-2022: 94.7%Estimated number of melanoma survivors in 2023: 1,573,288Source: National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Melanoma of the Skin. Available at https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html. Accessed July 19, 2026.\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\twe are here for you\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tFor more information or to schedule an appointment, call 844-346-7222. You can also schedule an appointment by calling the\u00a0RCCA location\u00a0nearest you.\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\trequest an appointment\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRELATED ARTICLES\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2 RCCA Oncologists Tell How Immunotherapies Are Increasing Survival in Advanced Melanoma\t\t\t\t\t\t\t\t\t\t\t\tImmunotherapies and other treatment advances have more than doubled the survival rate for advanced melanoma over the past 20 years, according to two board-certified medical\t\t\t\t\t\t\t\t\tLearn More\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tHow Is Hodgkin Lymphoma Different from Non-Hodgkin Lymphoma?\t\t\t\t\t\t\t\t\t\t\t\tIf you or a loved one has recently been diagnosed with Hodgkin or non-Hodgkin lymphoma, you may be wondering how these blood cancers differ. They\t\t\t\t\t\t\t\t\tLearn More\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tWhat Is Immunotherapy for Cancer? How It Works, Types, & Who Qualifies\t\t\t\t\t\t\t\t\t\t\t\tThe immune system is a powerful force that helps protect a person from diseases and illnesses. With advances in cancer research, scientists have discovered ways\t\t\t\t\t\t\t\t\tLearn More\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tRegional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t"},{"@context":"https:\/\/schema.org\/","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/www.regionalcancercare.org\/news\/#breadcrumbitem"},{"@type":"ListItem","position":2,"name":"Lymphedema in Breast Cancer Survivors: RCCA Oncologists Highlight 6 Key Points for Primary Care Clinicians","item":"https:\/\/www.regionalcancercare.org\/news\/managing-lymphedema-in-breast-cancer-survivors\/#breadcrumbitem"}]}]